

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

YEDA RESEARCH & DEVELOPMENT CO., LTD.,  
Patent Owner

---

U.S. Patent No. 8,399,413

---

Case IPR2015 Unassigned

---

**EXPERT DECLARATION OF ARI GREEN, M.D.  
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.  
PATENT NO. 8,399,413**

## TABLE OF CONTENTS

### Contents

I.	Qualifications and Background .....	1
A.	Education and Experience; Prior Testimony.....	1
B.	Bases for Opinions and Materials Considered .....	6
C.	Scope of Work .....	6
II.	Summary of Opinions.....	6
III.	Legal Standards .....	8
IV.	Person of Ordinary Skill in the Art.....	10
V.	The '413 Patent [Ex. 1001].....	11
VI.	Background.....	14
D.	Multiple Sclerosis.....	14
E.	Multiple Sclerosis Therapies.....	20
F.	Compliance and Adherence Rates with Disease Modifying Agents .....	26
VII.	Scope and Content of the Prior Art References.....	31
A.	PCT Publication No. WO 2007/081975 (“Pinchasi”) [Ex. 1005] .....	31
B.	Cohen et al. “Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS” <i>Neurology</i> 68:939- 44 (2007) (“Cohen”) [Ex. 1006] .....	32
C.	Flechter et al. “Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: Open multicenter study of alternate-day administration” <i>Clin. Neuropharm.</i> 29:11-15 (2002) (“Flechter	

	2002A”) [Ex. 1008].....	33
D.	Khan et al. “Randomized, Prospective, Rater-Blinded, Four Year Pilot Study to Compare the Effect of Daily Versus Every Other Day Glatiramer Acetate 20 mg Subcutaneous Injections in Relapsing-Remitting Multiple Sclerosis” <i>Multiple Sclerosis</i> 14:S296 (2008) (“Khan”) [Ex. 1010].....	35
D.	Flechter et al. “Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label-2-year follow up” <i>J. Neurological Sci.</i> 197:51-65 (2002) (“Flechter 2002B”) (Ex. 1012).....	36
E.	Caon et al. “Randomized, prospective, rater-blinded, four year pilot study to compare the effect of daily versus every other day glatiramer acetate 20 mg subcutaneous injections in RRMS” <i>Neurol.</i> 72(11)(Suppl. 3):P06.141 (March 17, 2009) (“Caon”) [Ex. 1011].....	37
F.	Johnson et al. “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis” <i>Neurol.</i> 45:1268-76 (July 1995) (“Johnson”) [Ex. 1018] .....	38
G.	Ge et al. “Glatiramer Acetate (Copaxone) treatment in Relapsing-Remitting MS Quantitative MR Assessment” <i>Neurology</i> 54:813-7 (2000) (“Ge”) [Ex. 1025] .....	39
H.	COPAXONE® 20 mg/ml Product Label (February 2009) (“2009 Copaxone Product Label”) [Ex. 1052].....	39
I.	Copaxone Summary Basis of Approval (NDA No. 20-622) “Copolymer 1 for treatment of relapsing-remitting multiple sclerosis” Review and Evaluation of Pharmacology Toxicology	

	Data (“SBOA”) (1996) [Ex. A of Ex. 1007] .....	40
J.	Jacobs et al. “Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis” <i>New Engl. J. Med</i> 343:898-904 (“Jacobs”) (September 2000) [Ex. 1054] .....	41
K.	Comi et al. “European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis” <i>Ann. Neurol.</i> 49:290-7 (2001) (“Comi”) [Ex. 1026] .....	42
VIII.	UNPATENTABILITY OF THE ’413 PATENT .....	43
A.	The Challenged Claims of the ’413 Patent Are Anticipated and Obvious Over Pinchasi [Ex. 1005].....	43
(a)	Independent Claims 1, 19 and 20 of the ’413 Patent are Anticipated by Pinchasi [Ex. 1005] .....	43
(b)	Claims 1, 19 and 20 of the ’413 Patent are Obvious Over Pinchasi [Ex. 1005] 53	
(c)	Dependent Claims 2-18 of the ’413 Patent are also Anticipated and Obvious in View of Pinchasi [Ex. 1005] .....	58
B.	All Claims of the ’413 Patent are Obvious Over Pinchasi [Ex. 1005] in view of Flechter 2002A [Ex. 1008] .....	62
IX.	CONCLUSION.....	65

1. My name is Ari Green, M.D. I have been retained by counsel for Mylan Inc. (“Mylan”). I understand that Mylan intends to petition for *inter partes* review of U.S. Patent No. 8,399,413 (the ‘413 patent) [Ex. 1001], which is assigned to Yeda Research & Development Co., Ltd. I also understand that Mylan will request that the United States Patent and Trademark Office cancel certain claims of the ‘413 patent as unpatentable in an *Inter Partes* Review petition. I submit this expert declaration, which addresses and supports Mylan’s *Inter Partes* Review petition for the ‘413 patent.

I. **Qualifications and Background**

A. **Education and Experience; Prior Testimony**

2. I received my Bachelor of Arts and Science (magna cum laude) from Miami University (OH) in 1994, and my M.D. from Duke University School of Medicine in 2001. I obtained my Master’s in Clinical Research from the University of California, San Francisco in 2007.

3. I completed postgraduate medical training at the University of California, San Francisco, completing an internship in the Department of Medicine in 2002, and a residency in Neurology in 2004. I became the Chief Resident of Neurology from 2004-2005, and a Clinical Fellow in the Departments of Neuro-Ophthalmology and Neuro-Immunology from 2005-2007. In 2006, I was a Visiting

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.